Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus

BACKGROUND: Modifications in the gut microbiota may be a crucial factor in the efficacy of canagliflozin (Cana) in managing patients with type 2 diabetes mellitus (T2DM). However, the interplay between oral and ocular surface microbiota and this treatment remains poorly explored. AIM: This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Limin, Liang, Chenghong, Song, Xiaojian, Jia, Xiaoyan, Wang, Xiudan, Zhang, Yun, Xie, Qinyuan, Zheng, Nan, Yuan, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586052/
https://www.ncbi.nlm.nih.gov/pubmed/37867512
http://dx.doi.org/10.3389/fendo.2023.1256292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586052/
https://www.ncbi.nlm.nih.gov/pubmed/37867512
http://dx.doi.org/10.3389/fendo.2023.1256292

Ejemplares similares